1. Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment
   K.-S.N. Atretkhany et al, 2016, Pharmacology & Therapeutics CrossRef
2. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
   Xiao-Ming Jiang et al, 2017, Acta Pharmacol Sin CrossRef
3. A nonimmune function of T cells in promoting lung tumor progression
   Jesse A. Green et al, 2017, J. Exp. Med. CrossRef
4. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
   K Kondo et al, 2017, Leukemia CrossRef
5. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
   Ross A Soo et al, 2018, Lung Cancer CrossRef
6. PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?
   David F. Heigener et al, 2017, Journal of Thoracic Oncology CrossRef
7. Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy
   Xianda Zhao et al, 2018, Pharmacology & Therapeutics CrossRef
8. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC
   Xue Li et al, 2018, Cancer Letters CrossRef
9. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels
   LiJun Xu et al, 2018, Mol Oncol CrossRef
10. Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma
    Xing Song et al, 2018, EBioMedicine CrossRef
11. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer
    Shuo Wang et al, 2018, FEBS Lett CrossRef
12. Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
    Daniel E Johnson et al, 2018, Nat Rev Clin Oncol CrossRef
13. Regulation and Function of the PD-L1 Checkpoint.
    Chong Sun et al, 2018, Immunity CrossRef
14. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma
    Ping-Chih Hsu et al, 2018, J Cell Mol Med CrossRef
15. Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma
    Yiwei Liu et al, 2018, Clinical Lung Cancer CrossRef
16. Molecular cross-talk of IL-6 in tumors and new progress in combined therapy
    Zuoqing Song et al, 2018, Thorac Cancer CrossRef
17. STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
    Ilaria Attili et al, 2018, Ther Adv Med Oncol CrossRef
18. Investigation of miR-136-5p key target genes and pathways in lung squamous cell cancer based on TCGA database and bioinformatics analysis
    Zu-cheng Xie et al, 2018, Pathology - Research and Practice CrossRef
19. Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer
    Kriti Ray et al, 2018, Cytokine & Growth Factor Reviews CrossRef
20. The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer
    Dongfang Tang et al, 2018, J Cell Mol Med CrossRef
21. “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
    Emira Bousoik et al, 2018, Front. Oncol. CrossRef
22. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers
    Chun-Chia Cheng et al, 2018, Molecular Carcinogenesis CrossRef
23. Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis.
    Li Sun et al, 2018, Cell Death Dis CrossRef
24. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia
    Shahrzad Jalali et al, 2018, Blood Adv CrossRef
25. Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer
    Spiros Vlahopoulos et al, 2018, Pharmacology & Therapeutics CrossRef
26. Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer.
    Spiros Vlahopoulos et al, 2019, Pharmacol Ther CrossRef
27. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
    Jinfang Zhang et al, 2018, Trends Biochem Sci CrossRef
28. MiR-940 Promotes the Proliferation and Migration of Gastric Cancer Cells through Up-regulation of Programmed Death Ligand-1 Expression
    Yibo Fan et al, 2018, Experimental Cell Research CrossRef
29. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
    Xianjie Jiang et al, 2019, Mol Cancer CrossRef
30. Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma
    Cheng Xu et al, 2018, Chinese Medical Journal CrossRef
31. Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.
    Nobuhide Higashino et al, 2019, Lab Invest CrossRef
32. Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells
    Wenyi Gu et al, 2019, Clin Exp Pharmacol Physiol CrossRef
33. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling
    Ming-Shao Tsai et al, 2019, Oral Oncology CrossRef
34. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
    Mingjing Shen et al, 2019, J Exp Clin Cancer Res CrossRef
35. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
    Miyuki Sato et al, 2019, PLoS One CrossRef
36. CSTP1 inhibits IL-6 expression through targeting Akt/FoxO3a signaling pathway in bladder cancer cells
    Dexiang Zhuo et al, 2019, Experimental Cell Research CrossRef
37. Nimotuzuma restrains proliferation and induces apoptosis in human osteosarcoma cells by regulation of EGFR/PI3K/AKT signal pathway
    Meihan Liu et al, 2019, J Cell Physiol CrossRef
38. Exploring Tumor-Intrinsic PD-L1 Signal with Proximity-Dependent Biotin Identification in Lung Cancer Cells
    Tiepeng Li et al, 2019, Biochemistry CrossRef
39. ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer
    Iris C. Salaroglio et al, 2019, IJMS CrossRef
40. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
    Xiangfeng Shen et al, 2019, Front. Immunol. CrossRef
41. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging
    Dan Li et al, 2019, Mol. Pharmaceutics CrossRef
42. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
    Yang Zhang et al, 2019, Respir Res CrossRef
43. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
    Ping-Chih Hsu et al, 2019, IJMS CrossRef
44. Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions
    Shohreh Azadi et al, 2019, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research CrossRef
45. Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors
    Sahyun Pak et al, 2019, J Cancer Res Clin Oncol CrossRef
46. PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
    Yilun Wu et al, 2019, Front. Immunol. CrossRef
47. STAT3, a Master Regulator of Anti-Tumor Immune Response
    null Rébé et al, 2019, Cancers CrossRef
48. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
    Anqi Lin et al, 2019, Mol Cancer CrossRef
49. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils
    Anquan Shang et al, 2019, J Exp Clin Cancer Res CrossRef
50. Interleukin‐17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma
    Aeri Aotsuka et al, 2019, Cancer Sci CrossRef
51. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma
    Byung Soo Lee et al, 2017, Biochemical and Biophysical Research Communications CrossRef
52. The potential and controversy of targeting STAT family members in cancer.
    Yannick Verhoeven et al, 2020, Semin Cancer Biol CrossRef
53. STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
    null Zerdes et al, 2019, Cancers CrossRef
54. PD-L1 and PD-1 expressed in trigeminal ganglia may inhibit pain in an acute migraine model
    Suming Shi et al, 2019, Cephalalgia CrossRef
55. Mechanisms Controlling PD-L1 Expression in Cancer.
    Jong-Ho Cha et al, 2019, Mol Cell CrossRef
56. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment
    Li Yang et al, 2019, J Hematol Oncol CrossRef
57. The α9 Nicotinic Acetylcholine Receptor Mediates Nicotine-Induced PD-L1 Expression and Regulates Melanoma Cell Proliferation and Migration
    Hai Duong Nguyen et al, 2019, Cancers CrossRef
58. Oncogenic signaling pathways associated with immune evasion and the resistance to immune checkpoint inhibitors in cancer
    Yoshie Kobayashi et al, 2019, Seminars in Cancer Biology CrossRef
59. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer
    Katsuhiro Yoshimura et al, 2020, Lung Cancer CrossRef
60. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells
    Junyu Xiang et al, 2019, Gastroenterology CrossRef
61. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
    Shuling Zhang et al, 2020, International Immunopharmacology CrossRef
62. Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer
    Zhu Lingling et al, 2020, Pathology - Research and Practice CrossRef
63. IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-κB.
    Wen Liu et al, 2020, Cell Prolif CrossRef
64. Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
    Yiran Cai et al, 2020, BMC Cancer CrossRef
65. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Hiro Sato et al, 2020, Int J Clin Oncol CrossRef
66. Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
    Tamio Okimoto et al, 2020, Cancer Sci CrossRef
67. STAT3: Versatile Functions in Non-Small Cell Lung Cancer
    Julian Mohrherr et al, 2020, Cancers CrossRef
68. Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer
    Tae-Jung Kim et al, 2017, Oncotarget CrossRef
69. Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
    Zengzhi Lian et al, 2020, Thorac Cancer CrossRef
70. Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
    Rui Jin et al, 2020, Ther Adv Med Oncol CrossRef
71. Tobacco extracts promote PD‐L1 expression and enhance malignant biological differences via mTOR in gefitinib‐resistant cell lines
    Fengqi Xiao et al, 2020, Thorac Cancer CrossRef
72. Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers
    Yating Tang et al, 2018, Oncol Lett CrossRef
73. ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer.
    Lan Zhang et al, 2018, Mol Med Rep CrossRef
74. Positive PD‑L1 expression is predictive for patients with advanced EGFR wild‑type non‑small cell lung cancer treated with gemcitabine and cisplatin
    Yajuan Qiu et al, 2019, Oncol Lett CrossRef
75. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer
    Tung-Yung Huang et al, 2020, Cells CrossRef
76. Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors
    Kathrina L. Marcelo-Lewis et al, 2020 CrossRef
77. Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects
    Julia Delahousse et al, 2020, J Immunother Cancer CrossRef
78. Mechanisms of Cancer Resistance to Immunotherapy
    Rilan Bai et al, 2020, Front. Oncol. CrossRef
79. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells
    Chen Zhu et al, 2020, Front. Immunol. CrossRef
80. Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
    Yijun Jia et al, 2020, Front. Oncol. CrossRef
81. null
    Saul Suster et al, 2017 CrossRef
82. Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade
    Xinrui Zhao et al, 2020, Cancers CrossRef
83. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
    Elena Shklovskaya et al, 2020, IJMS CrossRef
84. Emerging role of tumor cell plasticity in modifying therapeutic response.
    Siyuan Qin et al, 2020, Signal Transduct Target Ther CrossRef
85. The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
    Giuseppe Lamberti et al, 2020, Cancers CrossRef
86. KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway
    Wenwen Du et al, 2020, Cell Death Differ CrossRef
87. Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer.
    Erwin Tomasich et al, 2021, Transl Res CrossRef
88. Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
    Muhammad Khan et al, 2020, Front. Immunol. CrossRef
89. ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
    Liangliang Cai et al, 2020, Front. Immunol. CrossRef
90. Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals
    Dae Young Lee et al, 2020, Seminars in Cancer Biology CrossRef
91. Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression
    Abilasha G. Jayathilake et al, 2020, BMC Complement Med Ther CrossRef
92. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer
    Yulong Fu et al, 2020, J Hematol Oncol CrossRef
93. Genomic Mutations of Primary and Metastatic Lung Adenocarcinoma in Chinese Patients
    Xinyu Chen et al, 2020, Journal of Oncology CrossRef
94. Immunomodulation by targeted anticancer agents
    Giulia Petroni et al, 2020, Cancer Cell CrossRef
95. Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
    Florida Voli et al, 2020, Cancer Res CrossRef
96. IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung
    Bo Jing et al, 2020, Cancer Res CrossRef
97. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
    Jiayi Yu et al, 2019, Clin Cancer Res CrossRef
98. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
    Jung-Mao Hsu et al, 2018, Cancer Res CrossRef
99. Antitumour immunity regulated by aberrant ERBB family signalling
    Shogo Kumagai et al, 2021, Nat Rev Cancer CrossRef
100. Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment.
     Yongbo Yu et al, 2021, Cell Death Discov CrossRef
101. Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer
     Juan Zhou et al, 2021, Lung Cancer CrossRef
102. IL-6 in inflammation, autoimmunity and cancer.
     Toshio Hirano, 2021, Int Immunol CrossRef
103. The PI3K /Akt/ mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies
     Nader Akbari Dilmaghani et al, 2021, IUBMB Life CrossRef
104. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
     Jingjing Qu et al, 2021, Ther Adv Med Oncol CrossRef
105. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
     Yannick Verhoeven et al, 2021, IJMS CrossRef
106. EGFR and PDL1: A Match (Not) Made in Heaven—A Real-World Retrospective Analysis of PDL1 Expression in EGFR-Mutated NSCLC
     Ullas Batra et al, 2021, Adv Ther CrossRef
107. PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
     Min Luo et al, 2021, Acta Pharmaceutica Sinica B CrossRef
108. Antitumor Effects of Ursolic Acid through Mediating the Inhibition of STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer Cells.
     Dong Young Kang et al, 2021, Biomedicines CrossRef
109. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
     Youqian Wu et al, 2021, Nat Commun CrossRef
110. The intersection of COVID-19 and cancer: signaling pathways and treatment implications
     Zhi Zong et al, 2021, Mol Cancer CrossRef
111. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
     Kenneth K. W. To et al, 2021, Front. Oncol. CrossRef
112. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
     Meng Qiao et al, 2021, Journal of Thoracic Oncology CrossRef
113. ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer
     Ah-Rong Nam et al, 2021, Cancer Letters CrossRef
114. PD-L1 Regulates Inflammation in LPS-Induced Lung Epithelial Cells and Vascular Endothelial Cells by Interacting with the HIF-1α Signaling Pathway
     Shilong Zhao et al, 2021, Inflammation CrossRef
115. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
     Jan Budczies et al, 2021, Cancer Immunol Immunother CrossRef
116. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer
     Tania Crombet Ramos et al, 2021, Front. Oncol. CrossRef
117. Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy
     Quan Cheng et al, 2021, Front. Cell Dev. Biol. CrossRef
118. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell–Mediated Antitumor Immunity Through PD‐L1
     Noreen Nog‐Qin Chui et al, 2021, Hepatol Commun CrossRef
119. PKCι regulates the expression of PDL1 through multiple pathways to modulate immune suppression of pancreatic cancer cells
     Hongmei Zhang et al, 2021, Cellular Signalling CrossRef
120. The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer
     Christophe Glorieux et al, 2021, Cancers CrossRef
121. Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor
     Siddharth Sourabh Sahu et al, 2021, ACS Appl. Mater. Interfaces CrossRef
122. Autophagy controls programmed death‑ligand 1 expression on cancer cells (Review)
     Lijuan Gao et al, 2021, Biomed Rep CrossRef
123. Abrogation of STAT3 activation cascade by Ginkgolide C mitigates tumourigenesis in lung cancer preclinical model
     Min Hee Yang et al, 2021 CrossRef
124. Development and Validation of an IL6/JAK/STAT3-Related Gene Signature to Predict Overall Survival in Clear Cell Renal Cell Carcinoma
     Chuanchuan Zhan et al, 2021, Front. Cell Dev. Biol. CrossRef
125. Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
     Xiaoxin Ren et al, 2021, Genes & Diseases CrossRef
126. Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
     Guoqing Qian et al, 2021, Mol Cancer Res CrossRef
127. Antibodies to EGF Receptor Family Members Can Upregulate Tumor Immunity
     Min Dai et al, 2021 CrossRef
128. Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy
     Shubhangi Gavali et al, 2021, IJMS CrossRef
129. Differential expression of long non-coding RNAs as diagnostic markers for lung cancer and other malignant tumors
     Li Li et al, 2021, Aging CrossRef
130. The genomic landscape of lung adenocarcinoma—insights towards personalized medicine
     Ovleen Kour et al, 2021, Proc.Indian Natl. Sci. Acad. CrossRef
131. Potential biomarkers and resistance mechanisms of atezolizumab in a patient with lung squamous cell carcinoma
     Kangqi Ren et al, 2021, Immunotherapy CrossRef
132. Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
     Nathaniel Wiest et al, 2021, Front. Oncol. CrossRef
133. MicroRNA-374a Promotes Hepatocellular Carcinoma Cell Proliferation by Targeting Mitogen-Inducible Gene 6 (MIG-6)
     Hui Li et al, 2018, oncol res CrossRef
134. Multicellular Effects of STAT3 in Non-Small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities
     Sagun Parakh et al, 2021, Cancers CrossRef
135. What is the current role of immunotherapy in EGFR mutant advanced NSCLC?
     Maria A Velez et al, 2021, Lung Cancer CrossRef
136. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
     Ichidai Tanaka et al, 2021, IJMS CrossRef
137. Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway
     Yao Lu et al, 2021, Front. Oncol. CrossRef
138. null
     Mohamad A. Salkeni et al, 2021 CrossRef
139. An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)
     Reza Elahi et al, 2022, International Immunopharmacology CrossRef
140. Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer
     Kang Chen et al, 2022, Front. Oncol. CrossRef
141. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
     Hirohito Yamaguchi et al, 2022, Nat Rev Clin Oncol CrossRef
142. Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment
     Priyanka Singh et al, 2022 CrossRef
143. Zinc Status Impacts the Epidermal Growth Factor Receptor and Downstream Protein Expression in A549 Cells
     Emily Scheiermann et al, 2022, IJMS CrossRef
144. The Lymph Node Microenvironment May Invigorate Cancer Cells With Enhanced Metastatic Capacities
     Tianhang Li et al, 2022, Front. Oncol. CrossRef
145. Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
     Paula Dobosz et al, 2022, IJMS CrossRef
146. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
     Mengling Wu et al, 2022, J Hematol Oncol CrossRef
147. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
     Giulia Petroni et al, 2022, Nat Rev Drug Discov CrossRef
148. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
     Robert J Motzer et al, 2022, J Immunother Cancer CrossRef
149. Immunomodulatory role of thrombin in cancer progression
     Eric T. Alexander et al, 2022, Molecular Carcinogenesis CrossRef
150. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer
     Yan Chen et al, 2022, Future Oncology CrossRef
151. Immunological effect of tyrosine kinase inhibitors on the tumor immune environment in non‑small cell lung cancer (Review)
     Li Jiang et al, 2022, Oncol Lett CrossRef
152. Targeting protein kinases benefits cancer immunotherapy
     Zhengkun Zhang et al, 2022, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
153. TMEM16A as a potential treatment target for head and neck cancer
     Kohei Okuyama et al, 2022, J Exp Clin Cancer Res CrossRef
154. Identification of Biomarkers Associated With CD8+ T Cells in Coronary Artery Disease and Their Pan-Cancer Analysis
     Shijian Zhao et al, 2022, Front. Immunol. CrossRef
155. Polysaccharide Peptide Induced Colorectal Cancer Cells Apoptosis by Down-Regulating EGFR and PD-L1 Expression
     Lin Jian et al, 2022, Iran J Pharm Res CrossRef
156. EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma
     Wenyue Zhao et al, 2022, International Immunopharmacology CrossRef
157. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
     Thomas Denize et al, 2022 CrossRef
158. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy
     James J. Kang et al, 2022, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
159. Non-small-cell lung cancer-associated gene mutations and inhibitors
     Ashwini Kumar et al, 2022, Advances in Cancer Biology - Metastasis CrossRef
160. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
     Kun Pang et al, 2022, Drug Resistance Updates CrossRef
161. A cohort study using IL-6/Stat3 activity and PD-1/PD-L1 expression to predict five-year survival for patients after gastric cancer resection
     Xiao Ning Li et al, 2022, PLoS ONE CrossRef
162. Targeting EGFR in Combination with Nutritional Supplements on Antitumor Efficacy in a Lung Cancer Mouse Model
     Chih-Hung Guo et al, 2022, Marine Drugs CrossRef
163. Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
     Kostas A. Papavassiliou et al, 2023, Cancers CrossRef
164. Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review)
     Jiao Deng et al, 2022, Oncol Lett CrossRef
165. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
     Itziar Otano et al, 2023, Nat Rev Clin Oncol CrossRef
166. Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
     Chen Jie et al, 2023, Front. Immunol. CrossRef
167. null
     Mei Lan Tan et al, 2023 CrossRef
168. MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation
     Yuan Wang et al, 2023, Cell Discov CrossRef
169. null
     David Terrero et al, 2023 CrossRef
170. Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors
     Shi-Yong Sun, 2023, Chinese Medical Journal - Pulmonary and Critical Care Medicine CrossRef
171. Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function
     Wei Zou et al, 2023, British J Pharmacology CrossRef
172. Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
     Shanshan Chen et al, 2023, Front. Immunol. CrossRef
173. Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
     Chang-Yao Chu et al, 2023, Sci Rep CrossRef
174. Comprehensive characterization of B7 family members in NSCLC and identification of its regulatory network
     Mintao Xiao et al, 2023, Sci Rep CrossRef
175. Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
     Natalie I. Vokes et al, 2023, Ther Adv Med Oncol CrossRef
176. Effects of Different Factors on the Efficacy of Anti PD-(L)1 Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer: An Observational, Retrospective Cohort Study
     Xiaoning Li et al, 2022, SSRN Journal CrossRef
177. Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
     Suna Zhou et al, 2023, Front. Immunol. CrossRef
178. Mutual connected IL-6, EGFR and LIN28/Let7-related mechanisms modulate PD-L1 and IGF upregulation in HNSCC using immunotherapy
     Junjun Li et al, 2023, Front. Oncol. CrossRef
179. First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer
     So Yeon Kim et al, 2023, Hematology/Oncology Clinics of North America CrossRef